Drug combo tested for Tough-to-Treat leukemia in frail patients

NCT ID NCT04150029

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and effectiveness of an experimental drug called MBG453 when given alongside two other drugs (azacitidine and venetoclax) to treat acute myeloid leukemia (AML). It was for adults newly diagnosed with AML who were considered unfit for intensive chemotherapy, often due to older age or other health problems. The trial was terminated early by the sponsor, so full results on how well it worked are not available.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

25Uni of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
Chattanooga Onc And Hem Assoc PC

Chattanooga, Tennessee, 37404, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Univ Medical Center

Durham, North Carolina, 27710, United States
Huntsman Cancer Institute Univ of Utah

Salt Lake City, Utah, 84112 0550, United States
Levine Cancer Insitute Carolinas Healthcare System

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center University of Texas

Houston, Texas, 77030, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering

New York, New York, 10017, United States
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Vancouver, British Columbia, V5Z 1M9, Canada
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Fukushima, Fukushima, 960 1295, Japan
Novartis Investigative Site

Yamagata, Yamagata, 990 9585, Japan
Novartis Investigative Site

Seoul, Seocho gu, 06591, South Korea
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Uni Of Iowa Hospitals And Clinics

Iowa City, Iowa, 52242, United States
Weill Cornell Medicine NY-Presb

New York, New York, 10021, United States
Yale University School Of Medicine

New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA